Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Stephen Rubino, Ph.D. has been appointed Chief Business Officer. Dr. Rubino has more than 25 years of strong commercial and strategic development experience in the pharmaceutical and biotechnology industry, including 17 years at Novartis. He will serve on the executive leadership team and will lead business and corporate development for Celyad.

“We are excited to have Stephen join Celyad as we continue to grow our executive team’s presence in the U.S. while broadening our global perspective of the industry,” said Filippo Petti, Chief Executive Officer of Celyad. “Stephen has tremendous business development and commercial experience both in and out of the U.S., including directing the commercial development of products that will be invaluable as we advance our clinical CAR-T programs.”  

Most recently, Dr. Rubino was Chief Business & Strategy Officer at Omega Therapeutics. Prior to this position, Dr. Rubino served as Global Head of Business Development and Licensing and New Product Marketing for the Cell and Gene Therapies business unit at Novartis. There, he led growth opportunities including evaluation, licensure and commercial development across a pipeline of cell therapy products. He currently sits on the board of Sermonix Pharmaceuticals and Ilkos Therapeutic. Dr. Rubino received a Ph.D. in virology from Cornell University and an M.B.A. from Baruch College.

Download press release(s)

Press release

70.23 Ko

Communiqué de presse

115.55 Ko

Persbericht

70.20 Ko

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Next News

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call